Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant
Por um escritor misterioso
Descrição
PDF) A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma
Castration Resistant Prostate Cancer: Developments & Challenges in 2020
Nivolumab Plus Ipilimumab Demonstrates Anti-Tumor Activity in Metastatic Castration-Resistant Prostate Cancer
Frontiers Phase II Study of Ipilimumab in Men With Metastatic Prostate Cancer With an Incomplete Response to Androgen Deprivation Therapy
ICU :: Investigative and Clinical Urology
Nivolumab plus ipilimumab shows benefit in advanced prostate cancer subset
Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial - The Lancet Oncology
Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer.
Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies - McGregor - 2021 - Cancer - Wiley Online Library
Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
ASCO GU 2021 - News Archives - Onco Americas
Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment
PDF) Metastatic Castration-Resistant Prostate Cancer, Immune Checkpoint Inhibitors, and Beyond
Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial - ScienceDirect
de
por adulto (o preço varia de acordo com o tamanho do grupo)
